Market Access Is AI the missing link in fixing MLR – or the reason it brea... Somewhere in a shared drive at a mid-size pharma company, there is a folder labelled “Q3 Messaging FINAL v3 (2).” Inside it are three Word documents with tracked changes from four people, n
Digital We can’t fix modern healthcare with 1950s solutions. AI is t... In today’s NHS, the urgency of embracing artificial intelligence (AI) is no longer a matter of innovation - it’s a matter of survival.
Patients Responding to global greying: Does Nordic AgeTech hold the b... It’s a fact of life that we’re all living longer, which is reshaping the way healthcare is delivered.
Digital What is the future of technology in health data? From robot-assisted surgery to personalised disease treatment - technology can do some truly remarkable things.
Digital From pilots to impact: What it really takes to scale GenAI i... Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of-concepts.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
